Microbiome Research: New Therapies for Gut Health

A 2026 narrative review from Frontiers in Cellular and Infection Microbiology details a critical, yet often overlooked, factor in cancer treatment success: the patient’s gut microbiome. The paper, authored by Marjanović and colleagues, synthesizes evidence showing how gut bacteria can make or break the effectiveness of a specific, powerful class of cancer drugs used for colorectal cancer.

The drugs, called immune checkpoint inhibitors (ICIs), are a major advance for treating cancers with specific genetic features, known as MSI-H/dMMR colorectal cancer. However, a significant number of patients either don’t respond at all (primary resistance) or stop responding over time (acquired resistance). The review identifies the gut microbiome-immune axis as a key regulator of this resistance, opening new paths for improving patient outcomes.

The Microbial Gatekeepers of Cancer Immunotherapy

The central argument of the review is that the gut microbiome acts as a master modulator of the body’s immune system. In the context of cancer, the effectiveness of ICIs depends entirely on reviving the host’s own immune cells to attack tumors. The gut microbiome, through constant communication with the immune system, either supports or suppresses this revival.

Marjanović et al. describe this as a complex axis where the composition of bacterial communities, the molecules they produce, and local gut immunity directly influence the wider tumor microenvironment. A favorable microbiome can “prime” the immune system for a robust response to ICIs. An unfavorable one can shut it down before it even begins.

How Gut Bacteria Talk to Tumors: The Role of Metabolites

The mechanisms behind this communication are rooted in microbial metabolism. The review team highlights several key classes of bacterial metabolites that serve as chemical messengers.

Short-chain fatty acids (SCFAs), like butyrate, are produced by fermenting dietary fiber. While often considered anti-inflammatory, their role in cancer immunotherapy is context-dependent; certain levels and types may be necessary for optimal immune function. Bile acids, modified by gut bacteria, can influence immune cell activity within the gut and beyond.

Perhaps most intriguing is the tryptophan pathway. Gut bacteria metabolize dietary tryptophan into compounds that can either activate immune-regulatory pathways or promote inflammatory responses. The balance of these metabolites appears critical. Other molecules like inosine and polyamines also have documented effects on T-cell function and tumor growth.

An imbalance in these metabolic pathways—often stemming from a state of gut dysbiosis—is what the authors link to ICI resistance. This connects cancer research directly to the broader science of gut health, where similar imbalances are implicated in conditions like IBS and IBD.

Turning Insight into Action: Biomarkers and Therapies

A direct implication of this research is the search for microbiome-based biomarkers. Analyzing a patient’s gut microbiome before treatment could predict their likelihood of responding to ICIs. This moves toward a more personalized, precision oncology approach.

More actively, researchers are testing interventions designed to sculpt a treatment-friendly microbiome. These include:

• Fecal Microbiota Transplantation (FMT): Transferring stool from a patient who responded well to ICIs to a new patient, with early trials showing potential to overcome resistance.
• Precision Probiotics and Live Biotherapeutics: Moving beyond generic supplements to consortia of bacteria with specific, known immunomodulatory functions.
• Selective Antimicrobials: Using narrow-spectrum antibiotics or bacteriophages to remove harmful, resistance-linked bacteria without wiping out the entire microbial community. This approach is of particular interest given the careful use of antibiotics like rifaximin in managing SIBO.
• Dietary Interventions: Using specific fibers, prebiotic (prebiotic fiber supplement)s, or dietary patterns to nourish beneficial, immunotherapy-supporting bacterial groups. This aligns with broader research on how plant fibers and phytochemicals shape the gut-immune axis.

A Promising Field with Translational Hurdles

The authors conclude that the gut microbiome-immune axis is a legitimate and promising target for improving cancer immunotherapy. However, they are clear about the challenges.

Much of the strongest evidence is still from animal studies. Human studies are often small, observational, or from early-phase trials. A major priority is conducting larger, prospective trials with standardized methods for microbiome analysis. Furthermore, the complex interplay between diet, existing medications, host genetics, and the microbiome means that a one-size-fits-all approach is unlikely to work.

The path forward, as outlined by Marjanović and the team, requires a collaborative effort: deeper mechanistic research, longitudinal tracking of patients’ microbiomes during treatment, and the careful, rational development of microbiome-directed therapies. If these hurdles can be addressed, modulating the gut microbiome could become a standard adjunct therapy, helping more patients achieve lasting benefits from immunotherapy.

Source: Marjanović M, Maletin N, Kukić B, et al. Gut microbiome-mediated primary and acquired resistance to immune checkpoint inhibitors in MSI-H/dMMR colorectal cancer: mechanisms, biomarkers, and therapeutic implications-a narrative review. Front Cell Infect Microbiol. 2026;16:1907957. doi: 10.3389/fcimb.2026.1907957. PMID: 42755803.